Challenge
A top-10 biopharma had just undergone a multi-billion-dollar merger and faced a sprawling manufacturing network of over 150 partners in over 400 sites. The company sought to simplify this network and drive major COGS reductions.
Approach
Evaluated all supply and demand requirements for their rapidly expanding portfolio, with a total of 16 categories for SM and LM network, including cutting-edge modalities. Through deep diligence, RFI/ RFPs and workshops, developed CDMO small and large molecule Network strategy to collapse supplier sites from >300 to 26 Strategic partners.
Impact
Helped to drive a unified CDMO network vision, and helped execute this via partner down-selection, negotiation and embedding to practice. This network: (1) ensured capacity coverage, quality, and capability, while recognizing a ~12% savings; (2) reduced # competitive bids by >80%, with 95% adherence, and (3) developed and rolled out training, governance and communications.
